| Drug Name: | Maprotiline (10262-69-8) |
|---|---|
| PubChem ID: | 4011 |
| SMILES: | CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24 |
| InchiKey: | QSLMDECMDJKHMQ-UHFFFAOYSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic Uptake Inhibitors, Antidepressive Agents, Central Nervous System Agents, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Psychotropic Drugs |
| Molecular Weight (dalton) | : | 277.411 |
| LogP | : | 4.2114 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 1 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 12.03 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Toxicity And Inefficacy | CYP2D6 (P10635) | Toxicity in poor metabolisers@ inefficacy in ultrarapid metabolisers. [ ADR Type 3 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category